Ten Years on a Drug Nobody Ever Meant to Be Permanent
A single patient on a decade-old prescription nobody ever re-examined. The disagreement isn't about whether to eventually stop it — both agree on that — it's about whether the symptoms that show up during the taper mean anything at all.
Carol M., a 61-year-old retired postal supervisor, has taken omeprazole every morning for so long she genuinely can't remember why it was started — "heartburn, sometime in my forties," is the most specific answer she can give. She feels well, has no active reflux symptoms she can identify, and was mildly surprised when her new primary care physician flagged the prescription itself as worth discussing rather than simply renewing it at her annual physical, the way it's been renewed for roughly a decade.
Nobody ever actually re-diagnosed her reflux or confirmed she still needs the drug — the prescription simply outlived the visit that started it, which is exactly the pattern the deprescribing literature describes as the most common route into long-term PPI use. A recent DEXA scan showed osteopenia, and her most recent labs show a creatinine trending upward over three years, both findings that sit inside the observational literature linking chronic PPI use to reduced calcium absorption, fracture risk, and CKD progression — associations, not proven causation, but real enough that the AGA's clinical practice update on deprescribing proton pump inhibitors (Targownik and colleagues) recommends attempting a trial of discontinuation in patients without a documented ongoing indication.
What makes simply stopping the drug harder than it sounds is rebound acid hypersecretion: chronic acid suppression drives compensatory gastrin elevation, and stopping abruptly can produce a genuine surge in acid output and symptoms that, in a patient who was actually asymptomatic to begin with, can be mistaken for proof she needed the drug after all — a real pharmacologic phenomenon, not a psychological one, and the reason deprescribing this class is a tapering process rather than a single stop-the-refill decision. The magnitude of that rebound is dose- and duration-dependent: patients on higher long-term doses, and those tapered abruptly rather than stepwise, report more pronounced and longer-lasting symptom recurrence in the deprescribing literature — a detail that argues directly for a graded step-down over several weeks rather than the blunt stop her chart's decade of unexamined renewals might otherwise invite.
The prescription that outlived its own reason
Nothing in her chart documents an actual indication for this drug anymore — no endoscopy, no confirmed GERD diagnosis, just a decade of renewals. Against that, her osteopenia and her rising creatinine both sit inside the exact risk profile the deprescribing literature associates with chronic PPI use.
I don't think the standard should be proving she doesn't need it — it should be that nobody has actually shown she does. I'd start tapering her off now.
I agree the indication is genuinely undocumented, and I'm not arguing to keep her on it indefinitely by default.
What I'd add before we stop anything is that chronic acid suppression drives compensatory gastrin elevation, and abrupt discontinuation can produce real rebound hyperacidity — heartburn that shows up two to four weeks after stopping isn't necessarily her original disease reasserting itself, it can be the withdrawal phenomenon itself. If we don't taper deliberately and tell her what to expect, she's likely to reinterpret rebound symptoms as proof she needed the drug all along and go right back on it.
That's a fair distinction, and I'd rather build the taper around it than have her restart the drug for the wrong reason six weeks from now.
Step-down dose over several weeks, H2-receptor antagonist available as a bridge if symptoms appear, and an explicit conversation with her now about what rebound might feel like so she isn't blindsided by it — with real follow-up on the osteopenia and vitamin D independent of whatever happens with the taper.
A structured 4-6 week taper agreed on, with famotidine available as a bridge and Carol explicitly told what rebound hyperacidity might feel like so she can tell it apart from a genuine return of her original symptoms, plus separate follow-up for her osteopenia and vitamin D.
Both physicians agreed on the plan itself; what remains open is what happens if she is one of the patients whose reflux turns out to be real and simply asymptomatic on suppression — a possibility neither position denies, and the reason the taper is being run as a genuine trial rather than a foregone stop.